PPMI Completed & Ongoing Biologic Analyses

	Principal Investigator	Organization	Project Title	Data Availability	Analyte	Matrix	Included Enrollment Cohorts	Subcategories included	Visit(s)	Project ID	Notes	Publications
	Collaboration powered by Smartsheet   |   Report Abuse
1	Andrew Singleton, PhD	NIA	APOE4 Genotyping​	Currently available	APOE4 genotyping​	DNA from whole blood	Healthy ControlParkinson DiseaseSWEDD (legacy)	N/A	Baseline	104		https://doi.org/10.1016/s1474-4422(15)00178-7
2	Clemens Scherzer, MD	Harvard	Evaluation of PD-linked Transcripts in PPMI	Currently available	aSyn transcripts	RNA from whole blood	Healthy ControlParkinson Disease	N/A	Baseline	105		https://pubmed.ncbi.nlm.nih.gov/26220939/ https://doi.org/10.1016/j.parkreldis.2015.10.265 https://doi.org/10.21203/rs.3.rs-6837659/v1
3	Andrew Singleton, PhD	NIA	Selected Genetic Variants Genotyped Using NeuroX Array	Currently available	NeuroX genotyping	DNA from whole blood	Healthy ControlParkinson DiseaseProdromalSWEDD (legacy)	Genetic subjects	Baseline	106, 107		https://doi.org/10.1371/journal.pone.0175674
4	Andrew Singleton, PhD	NIA	Immunochip Genotyping on DNA Samples from PPMI	Currently available	Immunochip genotyping​	DNA from whole blood	Healthy ControlParkinson DiseaseSWEDD (legacy)	N/A	Baseline	108		https://doi.org/10.1016/s1474-4422(15)00178-7
5	Les Shaw, PhD	UPenn	A-beta 1-42, t-tau and p-tau 181 Measurements in PPMI CSF Samples using xMAP/Luminex Multiplex Immunoassay & Roche Elecsys	Currently available	Aβ, tau, & p-tau181 ​	CSF	Healthy ControlParkinson DiseaseProdromalSWEDD (legacy)	Genetic subjects	Baseline, 6, 12, 24, 36 months	110, 125	Innogentics: PD, HC, & SWEDD through yr 1; Elecsys: PD, HC, & SWEDD through yr 3, prodromal & genetic through yr 1	https://doi.org/10.1001/jamaneurol.2013.3861 https://doi.org/10.1007/s00401-016-1552-2 https://doi.org/10.1212/wnl.0000000000004609
6	Alice Chen-Plotkin, MD, MSc	UPenn	Plasma Apolipoprotein A1 Level as a Biomarker in Parkinson’s Disease	Currently available	ApoA1 & EGF​	Plasma	Healthy ControlParkinson Disease	N/A	Baseline, 6, 12 months	112		https://doi.org/10.1002/mds.26290
7	Maria Teresa Pellecchia, PhD	University of Salerno	Insulin-like Growth Factor-1 as a Biomarker of Early Cognitive Impairment in PD	Currently available	IGF-1	Serum	Healthy ControlParkinson Disease	N/A	Baseline	113		https://doi.org/10.1371/journal.pone.0186508
8	Judith Potashkin, PhD	Rosalind & Franklin University	Whole blood RNA Biomarkers of PD	Currently available	mRNA transcripts	RNA from whole blood	Healthy ControlParkinson Disease	N/A	Baseline	114		https://doi.org/10.1371/journal.pone.0142582
9	Matthew Farrer, PhD	University of BC	Clinical, Imaging, & Plasma & CSF Correlates of aSyn Genomic Variability	Currently available	SNCA genotyping​	DNA from whole blood	Healthy ControlParkinson Disease	N/A	Baseline	115
10	Andrew Singleton, PhD	NIA	Exome Sequencing of PPMI samples	Currently available	Whole exome sequencing	DNA from whole blood	Healthy ControlParkinson DiseaseSWEDD (legacy)	N/A	Baseline	116		https://doi.org/10.1002/mds.26374
11	Andrew Singleton, PhD	NIA	Whole Genome Sequencing & Analysis of PPMI Prodromal & Genetic Cohorts & Genetic Registry​	Currently available	Whole genome sequencing	DNA from whole blood	Healthy ControlParkinson DiseaseProdromalSWEDD (legacy)	Genetic subjects	Baseline	118		https://doi.org/10.1002/acn3.644
12	Martin Rabey, MD	BioShai Ltd.	Validation of a blood-based Gene Expression Assay for Early Diagnosis & Monitoring Disease	Currently available	mRNA transcripts	RNA from whole blood	Healthy ControlParkinson DiseaseSWEDD (legacy)	N/A	Baseline, 12, 24, 36 months	119
13	Dena Hernandez, PhD	NIA​	DNA Methylation in PPMI	Currently available	DNA methylation	DNA from whole blood	Healthy ControlParkinson DiseaseSWEDD (legacy)	N/A	Baseline	120
14	Thomas Kremer, PhD; Kristen Taylor, PhD	Roche	CSF Neurotransmitter Metabolites as Promising Diagnostic & Disease Severity Biomarkers in Early-Stage PD Patients​	Currently available	Catecholamines​	CSF	Healthy ControlParkinson Disease	N/A	Baseline, 12, 24 months	122		https://doi.org/10.1002/mds.28608
15	Dwight German, PhD	UT Southwestern	Blood Biomarker for PD	Currently available	PD2 peptoid	Serum	Healthy ControlParkinson Disease	N/A	Baseline	123		https://doi.org/10.1038/s41531-018-0064-2
16	Peggy Taylor, PhD	BioLegend	aSyn Measurements in Longitudinal CSF Samples From De Novo, PD, CT, SWEDD, Prodromal, & Genetic Cohorts​	Currently available	total aSyn, hemoglobin, & total protein	CSF	Healthy ControlParkinson DiseaseProdromalSWEDD (legacy)	Genetic subjects	Baseline, 6, 12, 24, 36 months	124, 134	PD, HC, SWEDD through yr 3, prodromal & genetic through yr 1	https://doi.org/10.1002/mds.27806 https://pubmed.ncbi.nlm.nih.gov/29030452/ https://pubmed.ncbi.nlm.nih.gov/31361367/ https://pubmed.ncbi.nlm.nih.gov/30564614/
17	Andrew Singleton, PhD	NIA	GBA Sequencing	Currently available	GBA sequencing	DNA from whole blood	Healthy ControlParkinson DiseaseSWEDD (legacy)	N/A	Baseline	126		https://doi.org/10.1002/mds.26374
18	Satpal Virdee, PhD	University of Dundee​	Profiling PINK1-Parkin Functionality in Patient Fibroblasts Using Chemical Probes	Currently available	PINK1	Fibroblasts	Healthy ControlParkinson Disease	N/A	N/A	127
19	Xinnan Wang, PhD	Stanford University​	Miro, a Biomarker for Parkinson’s Disease	Currently available	Miro	FibroblastsiPSCs	Healthy ControlParkinson DiseaseProdromal	Genetic subjects	N/A	129		https://doi.org/10.1016/j.cmet.2019.08.023 https://doi.org/10.3389/fnmol.2021.734273 https://doi.org/10.3389/fcell.2021.765408
20	Gavin Hudson, PhD	Newcastle University	The Role of Cell-Free Mitochondrial DNA in Neurodegenerative Disease	Currently available	Cell-free mitochondrial Dna	CSF	Healthy ControlParkinson Disease	N/A	Baseline, 36 months	130		https://doi.org/10.1186/s13024-020-00362-y
21	Kendall Van Keuren-Jensen, PhD	TGen Foundation	RNAseq in PPMI	Currently available (summary files, raw data for cloud transfer, & data explorer)​	mRNA& miRNA sequencing​	RNA from whole blood	Healthy ControlParkinson DiseaseProdromalSWEDD (legacy)	Genetic subjects	Baseline, 6, 12, 24, 36 months	131, 133	Data available as summary files, raw data for cloud transfer, & data explorer	https://doi.org/10.1038/s43587-021-00042-6 https://doi.org/10.1038/s43587-021-00088-6
22	Pablo Sardi, PhD	Sanofi	GBA-Related Biomarkers in Parkinson's Disease	Currently available	GCase activity & sphingolipids​	CSFPlasmaWhole blood	Healthy ControlParkinson DiseaseSWEDD (legacy)	N/A	Baseline, 12, 24, 36 months	132, 135		https://doi.org/10.1038/s41531-021-00241-3 https://doi.org/10.1002/mds.28472 https://doi.org/10.1002/acn3.51164
23	Nilima Prakash, PhD	Hamm-Lippstadt University of Applied Sciences​	Altered Calcium Activity Patterns in Developing Dopaminergic Neurons from PD Patients as an Early Indicator of Disease Predisposition or Progression	Currently available	Calcium activity	FibroblastsiPSCs	Healthy ControlParkinson Disease	N/A	N/A	136
24	Rachit Bakshi, PhD	MGH/MIND​	Urate & Nrf2 Pathway Effects on Mutant LRRK2 Toxicity in iPSC-Derived DA Neurons	Currently available	Urate & Nrf2​	iPSCs	Healthy ControlParkinson DiseaseProdromal	LRRK2 subjects	N/A	137
25	Travis Dunckley, PhD; Paula Desplats, PhD	Arizona State University; UCSD	Comprehensive Methylation Profiling of the PPMI Cohort​	Currently available	Methylation profiling​	DNA from whole blood	Healthy ControlParkinson DiseaseProdromal	LRRK2 subjects	Baseline, 12, 24, 36 months	140
26	Nic Dzamko, PhD	University of Sydney​	Inflammatory phenotypes in differentiated human LRRK2 & GBA mutation IPS cell lines	Currently available	Inflammation/​lysosomal function	iPSCs	Healthy ControlParkinson DiseaseProdromal	GBA & LRRK2 subjects	N/A	141		https://doi.org/10.3389/fncel.2023.1229213 https://doi.org/10.1186/s40035-024-00448-3
27	Danielle Graham, PhD; Brit Mollenhauer, MD	Biogen; Paracelsus EleN/A Klinik	Investigation of Neurofilament Light Chain in Serum from the PPMI Cohorts as Progression Marker for PD​	Currently available	Neurofilament Light (NFL)​	Serum	Healthy ControlParkinson DiseaseProdromal	Genetic subjects	PD & HC: Baseline, 6, 12, 24, 36, 60 months; Prodromal & genetic cohorts: Baseline, 6, 12, 24, 36 months	144		https://doi.org/10.1002/mds.28206
28	Kalpana Merchant, PhD	TransThera	Do Urinary BMP Levels Change with Disease Progression in Idiopathic & Genetic PD?	Currently available	BMP	Urine	Healthy ControlParkinson DiseaseProdromal	GBA & LRRK2 subjects	PD, HC, & GBA: Baseline only; LRRK2: Baseline, 12, 24 months	145		https://doi.org/10.1038/s41531-023-00468-2
29	Dimitri Krainc, MD	Northwestern University	Convergence of LRRK2 & GBA1 in the Pathogenesis of Parkinson’s Disease	Currently available	GCase activity in dopaminergic neurons​	iPSCs	Healthy ControlParkinson Disease	LRRK2 subjects	N/A	148		https://doi.org/10.1038/s41467-025-57142-9
30	Matt LaVoie, PhD	Brigham & Women’s, Harvard​	Role of LRRK2 in Gcase-mediated Alterations in Lysosome Functions & aSyn Metabolism	Currently available	LRRK2 at lysosomes	iPSCs	Parkinson Disease	GBA subjects	N/A	149
31	Andy Singleton, PhD	NIA	The Foundational Data Initiative	Currently available	Transcriptional activity, gene regulation, epigenetics​	iPSCs	Healthy ControlParkinson DiseaseProdromalSWEDD (legacy)	Genetic subjects	N/A	150	Data portal under development	https://doi.org/10.1016/j.xgen.2023.100261
32	Fiona Elwood, PhD	Novartis	Identification of Proteins & Protein Networks in Human CSF That Differentiate Within PD Patients​	Currently available	SomaLogic collaboration (with Merck & Novartis)​	CSF	Healthy ControlParkinson DiseaseProdromal	Genetic subjects	Baseline	151		https://doi.org/10.1038/s41531-023-00461-9
33	Richard Batrla-Utermann, PhD	Roche	Roche NeuroTool Kit	Currently available	Roche Elecsys NeuroTool Kit (aSyn, GFAP, IL-6, S100b, neurogranin, NFL, sTREM2, YKL40)​	CSF	Healthy ControlParkinson Disease	N/A	Baseline, 6, 12, 24, 36, 48 months	152		https://doi.org/10.1371/journal.pone.0257372
34	Thomas Schwarz, PhD	Boston Children’s Hospital​	Mitochondrial Transport Defects as a Potential Biomarker in Patient-derived Cells	Currently available	Mitochondrial transport​	iPSCs	Healthy ControlParkinson Disease	Genetic subjects	N/A	153
35	Claudio Soto, PhD	Amprion	Monitoring the Progression & Pre-clinical Diagnosis of PD by Detection of aSyn Oligomers in CSF Using the PMCA Assay	Currently available	aSyn seeding (PMCA)- Round Robin & Phase 2​	CSF	Healthy ControlParkinson DiseaseProdromalSWEDD (legacy)	Genetic subjects	Phase 1: Baseline, 36, mo; Phase 2: PD, HC, SWEDD at Baseline, prodromals at all visits, SNCA at all visits, LRRK2/GBA PD at Baseline and NMC at Baseline & all visits for phenoconverted	155	Phase 1 (bl & 36 months) PD, CT, SWEDD currently available; remaining data expected EOY	https://doi.org/10.1002/mds.28715 https://www.neurology.org/doi/10.1212/WNL.0000000000210279 https://doi.org/10.1016/s1474-4422(23)00109-6 https://doi.org/10.1186/s40478-021-01282-8 https://doi.org/10.1016/s1474-4422(25)00157-7
36	Aaron Day Williams, PhD	Flagship 60​	Investigation of Phenotypic Differences Between Familial PD, Idiopathic PD and Controls in Patient-derived iPSCs	Currently available	Phenotyping	iPSCs	Healthy ControlParkinson DiseaseProdromal	LRRK2 subjects	N/A	156
37	Marlene Jacobson, PhD	University of Dundee​	Investigating the Effect of Small Molecules to Rescue Lysosomal & GBA-1 Deficiencies in GBA-PD	Currently available	Lysosomal rescue​	Fibroblasts	Healthy ControlParkinson Disease	N/A	N/A	158
38	Les Shaw, PhD	UPenn	PPMI CSF A-beta42, t-tau, and p-tau 181 Analysis 2019	Currently available	Aβ, tau, & p-tau181 ​	CSF	Healthy ControlParkinson DiseaseProdromalSWEDD (legacy)	Genetic subjects	Baseline, 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 months	159	75 Bridging study & 2,000+ remaining PPMI samples not yet aN/Alyzed from previous efforts	https://doi.org/10.3233/JPD-212989
39	Sulev Koks, MD, PhD	Murdoch University	Association of Repetitive Elements with Parkinson's Disease Risk and Progression in the PPMI Cohort	Currently available	Tandem repeats	DNA from whole blood	Healthy ControlParkinson Disease	N/A	Baseline	160		https://doi.org/10.1038/s41531-021-00189-4
40	Maximiliano Gutierrez, PhD	Francis Crick Institute​	The Role of LRRK2 Kinase Activity in Human Macrophage Function	Currently available	LRRK2 kinase activity	iPSCs	Parkinson Disease	LRRK2 subjects	N/A	161		https://doi.org/10.1101/2023.09.27.559807
41	Liana Rosenthal, MD	Johns Hopkins	Is Poly ADP-ribose in the CSF a Biomarker for PD Diagnosis or Progression?​	Currently available	Poly ADP-ribose​	CSF	Healthy ControlParkinson Disease	N/A	Baseline, 6, 12, 18, 24, 36,48, 60 months	165
42	Eleanor Coffey, PhD	Turku Centre for Biotechnology​	PD Signature Validation Project Related to "Improving Patient Diagnosis, Stratification & Disease Monitoring in PD	Currently available	Protein handling	PBMCs	Healthy ControlParkinson DiseaseProdromal	Genetic subjects	3 longitudinal timepoints	170		https://pubmed.ncbi.nlm.nih.gov/41075160/
43	Cornelis Blauwendraat, PhD	NIA	Long read DNA sequencing of the PPMI cohort​	Expected Q2 2026	Long read Dna sequencing​	DNA from whole blood	Healthy ControlParkinson DiseaseProdromalSWEDD (legacy)	Genetic subjects	Baseline	171		https://www.medrxiv.org/content/10.1101/2025.08.14.25333596v1 https://doi.org/10.1101/gr.279159.124
44	Byron Caughey, PhD	NIH	aSyn Seeding Assay Round Robin- NIH​	Currently available	aSyn seeding​ (RT-QuIC)- Round Robin	CSF	Healthy ControlParkinson DiseaseSWEDD (legacy)	N/A	Baseline, 36 months	172		https://doi.org/10.1186/s40478-021-01282-8
45	Roland Heym, PhD	Abbvie	Evaluation of Seeding-competent aSyn in the CSF as a Biomarker for Parkinson’s Disease	Currently available	aSyn seeding​ (RT-QuIC)- Round Robin	CSF	Healthy ControlParkinson DiseaseSWEDD (legacy)	N/A	Baseline, 36 months	173		https://doi.org/10.1186/s40478-021-01282-8 https://doi.org/10.1101/2025.02.26.25322938
46	Dong-Gyu Jo, PhD	Sungkyunkwan University​	Study for the Propagation of aSyn (Screening the Propagation Relative Genes)	Expected Q1 2026	aSyn propagation	iPSCs	Healthy ControlParkinson Disease	GBA & LRRK2 subjects	N/A	174
47	Kirsten Taylor, PhD	Roche	aSyn PMCA Assay at Amprion	Currently available	aSyn seeding​ (PMCA in leftover samples)	CSF	Healthy ControlParkinson Disease	N/A	Baseline, 12, 24 months	176		https://doi.org/10.1002/mds.28608
48	Jennifer Van Eyk, PhD	Cedars-Sinai	Post-Translational Modification & Protein Quantification of Plasma & CSF	Currently available	Unbiased proteomics (DIA MS, AMP PD)	CSFPlasma	Healthy ControlParkinson Disease	N/A	Baseline & 3 longitudinal timepoints	177
49	Kimberly Billingsley, PhD	NIH	Identifying the Role of Structural Variants in PD	Expected Q2 2026	Structural variants	DNA from whole blood	Healthy ControlParkinson Disease	N/A	Various	179		https://doi.org/10.1002/ana.26608
50	Michael Schwarzschild, MD, PhD	MGH & Denali	Metabolomic Analysis of Penetrance, Prognosis, & Tracking Biomarkers of LRRK2 PD	Currently available	Metabolomics and Polyamines	CSFPlasma	Healthy ControlParkinson DiseaseProdromal	GBA & LRRK2 subjects	Plasma: Baseline,12, 24 months; CSF: Baseline only	180		https://pubmed.ncbi.nlm.nih.gov/32999056/ https://www.mdsabstracts.org/abstract/csf-cadaverine-and-other-polyamines-as-biomarkers-of-parkinsons-disease-a-ppmi-metabolomics-analysis/ https://www.mdsabstracts.org/abstract/lysosomal-lipid-dysregulation-in-parkinsons-disease-genetic-and-medication-effects-in-csf-metabolomics/ https://doi.org/10.1002/ana.25436 https://www.protocols.io/view/lc-ms-analysis-of-plasma-samples-from-ppmi-81wgbxe2ylpk/v1 https://www.mdsabstracts.org/abstract/lower-plasma-piperine-levels-in-parkinsons-disease-a-ppmi-metabolomics-analysis/ https://doi.org/10.1212/WNL.0000000000203912
51	Michael Schwarzschild, MD, PhD	MGH & Denali	Vitamin B12 levels in plasma samples	Currently available	B12	Plasma	Healthy ControlParkinson DiseaseProdromal	GBA & LRRK2 subjects	Plasma: Baseline,12, 24 months; CSF: Baseline only	243
52	Michael Schwarzschild, MD, PhD	MGH & Denali	Analysis of Glucosylsphingosine in CSF samples	Currently available	GlcSph	CSFPlasma	Healthy ControlParkinson DiseaseProdromal	GBA & LRRK2 subjects	Plasma: Baseline,12, 24 months; CSF: Baseline only	303
53	Marion Buckwalter, PhD	Stanford	Adaptive Immune Markers for Predicting Cognitive Decline in PD	Currently available	Immune profiling	CSFPlasma	Healthy ControlParkinson Disease	N/A	Baseline, 48 months	181
54	Shawn Ritchie, PhD	Med-Life Discoveries	Validation of Plasmalogen Augmentation as a Viable Drug Target in PD​	Currently available	Plasmalogen​	Plasma	Healthy ControlParkinson DiseaseSWEDD (legacy)	Genetic subjects	Baseline	182
55	Sebastian Virreira Winter, PhD	OmicEra​	Targeted & Untargeted MS Based Proteomics of Urine in PD	Currently available	Urine proteomics	Urine	Healthy ControlParkinson DiseaseProdromal	GBA & LRRK2 subjects	PD, HC, & GBA: Baseline only; LRRK2: Baseline, 12, 24 months	190		https://doi.org/10.1038/s44320-026-00190-0
56	Deniz Kirik, MD, PhD	University of Sydney	An in vivo approach to elucidate the pathobiology of PD-associated genes using human diseased neurons	Currently available	Whole genome sequencing on midbrain and cortical neurons and astrocytes	FibroblastsiPSCs	Healthy ControlParkinson Disease	N/A	N/A	193		https://doi.org/10.1038/s41531-025-01048-2
57	Alejandro Pezzulo, MD	University of Iowa	Multidisciplinary Analysis of Metabolic Dysregulation in Parkinson's Disease	Expected Q1 2026	Metabolic profiling	Fibroblasts	Healthy ControlParkinson Disease	N/A	N/A	194
58	Christos Proukakis, MD, PhD	University College London	Detection of GBA Mutations by Combination of Illumina & nanopore Sequencing​	Currently available	Long read GBA sequencing	DNA from whole blood	Parkinson DiseaseProdromal	GBA subjects	Various	195		https://doi.org/10.1038/s42003-022-03610-7
59	Eline Appelmans, PhD	FNIH	Targeted Proteomics in AMP PD	Currently available	Targeted proteomics (O-Link Explore 1536, AMP PD)​	CSFPlasma	Healthy ControlParkinson Disease	N/A	Baseline & 3 longitudinal timepoints	196		https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.70183
60	Xiqun Chen, MD, PhD	Mass General Hospital​	From Cancer Associations to Altered Immunity in the Pathogenesis of Parkinson’s Disease	Expected Q1 2026	Inflammation	iPSCs	Healthy ControlParkinson Disease	LRRK2 subjects	N/A	197
61	Erika Holzbaur, PhD	UPenn​	Investigating Mitochondrial Trafficking Deficits Across PD Models	Expected Q1 2026	Mitochondrial trafficking​	iPSCs	Healthy Control	Genetic subjects	N/A	198
62	Magdalene Moran, PhD	Caraway Therapeutics​	Developing TMEM175 Activators as Therapeutics for PD	Currently available	TMEM175 activators​	iPSCs	Parkinson Disease	GBA subjects	N/A	199
63	Jessie Ni, PhD	BioLegend	Bridging Study (Phase I) – PPMI CSF Samples	Currently available	Total aSyn, ​total protein (BioLegend)	CSF	Healthy ControlParkinson Disease	N/A	Baseline, 6, 12 months	200
64	Adam Mamais, PhD	University of Florida​	Converging Pathways of LRRK2 & PINK1 Biology Impacting Iron Homeostasis & Mitochondrial Function	Currently available	Iron & mitochondrial homeostasis​	iPSCs	Healthy ControlParkinson Disease	LRRK2 subjects	N/A	202		https://doi.org/10.1101/2025.09.26.678370 https://doi.org/10.1371/journal.pbio.3001480
65	Massimiliano Bianchi, PhD	Ulysses Neuroscience Ltd	Validation of microtubule dynamics as a novel target in Parkinson’s disease	Expected Q3 2026	Microtubule dynamics in midbrain-like 3D organoid cultures	iPSCs	Healthy ControlParkinson DiseaseProdromal	N/A	N/A	203
66	George Tofaris, MD, PhD	University of Oxford	Serum Neuronal Exosomes as Predictive or Dynamic Biomarkers in PD	Currently available	Neuronal exosomes (aSyn)​	Serum	Healthy ControlParkinson DiseaseProdromal	GBA, LRRK2	Baseline, 3, 6 Months	204		https://doi.org/10.1021/acs.analchem.3c00357 https://doi.org/10.1001/jamaneurol.2023.4398
67	Hiroaki Kaku, PhD	Western Michigan University​	The Role of FAIM in Parkinson’s Disease​	Expected Q2 2025	FAIM	iPSCs	Parkinson Disease	GBA & SNCA subjects	N/A	206
68	Karen MacLeod, Claudio Soto, PhD	Amprion	Development and Optimization of Semi-Quantitate PMCA for Analysis of Soluble ASYN Aggregates in CSF in Amprion's Clinical Laboratory	Currently available	aSyn seeding (PMCA)	CSF	Healthy ControlParkinson Disease	N/A	Various	207	Used warmed CSF from various visits	https://doi.org/10.1007/s00415-023-11810-2
69	Gallen Triana-Baltzer, PhD	Janssen	ptau 217 in the Parkinson Progression Marker Initiative (PPMI)	Currently available	Tau	Plasma	Parkinson Disease	LRRK2 subjects	Baseline	208
70	Bastian Zinnhardt, PhD	Roche	Identification of NLRP3 Inflammasome-related biomarkers in PPMI CSF Samples	Currently available	IL1B	CSF	Healthy ControlParkinson Disease	N/A	Baseline, 12, 24 Months	209
71	Anumantha Kanthasamy, PhD	Iowa State University	PPMI a-Syn Skin Seeding Assay	Currently available	aSyn seeding​ (RT-QuIC)- Round Robin	Skin	Healthy ControlParkinson Disease	N/A	Baseline	211
72	Bahareh Ajami, PhD; Dario Alessi, PhD	Oregon Health & Science University, University of Dundee	Investigating the influence of genetic risk factors of PD on peripheral immune cells to identify potential biomarkers for prediction of conversion of non-manifesting to manifesting carriers.	Partially available	Immune Cell Phenotyping, transcriptomics and proteomics”	PBMCsPlasma	Parkinson Disease	N/A	N/A	212, 213
73	Sarah Huntwork-Rodriguez, PhD	Denali	Metabolomic Analysis of Penetrance, Prognosis, & Tracking Biomarkers of LRRK2 PD	Currently available	GBA & Progranulin	CSFPlasma	Healthy ControlParkinson DiseaseProdromal	GBA & LRRK2 subjects	Plasma: Baseline,12, 24 months; CSF: Baseline only	215		https://pubmed.ncbi.nlm.nih.gov/32999056/ https://www.mdsabstracts.org/abstract/csf-cadaverine-and-other-polyamines-as-biomarkers-of-parkinsons-disease-a-ppmi-metabolomics-analysis/ https://www.mdsabstracts.org/abstract/lysosomal-lipid-dysregulation-in-parkinsons-disease-genetic-and-medication-effects-in-csf-metabolomics/ https://www.mdsabstracts.org/abstract/evaluation-of-the-pharmacodynamic-effects-of-biib122-dnl151-in-participants-with-lrrk2-mutation-driven-parkinsons-disease-beacon-study/
74	Khalil Ramadi, PhD	New York University	Neural Chemical Delivery System for Treatment of Parkinson's Disease	Expected Q3 2026	Dopamine neuronal cell survival, engraftment, and integration	FibroblastsiPSCs	Healthy ControlParkinson Disease	N/A	N/A	216
75	Mark Cookson, PhD	NIH	Lysosomal damage and LRRK2 activation	Expected Q1 2026	LRRK2 activity and lysosomal health	iPSCs	Healthy ControlParkinson Disease	LRRK2	N/A	218		https://doi.org/10.1371/journal.pbio.3001480
76	Julian Sefrin, PhD	Abbvie	Evaluation of TMPRSS5 (Spinesin) in the CSF as a potential biomarker for early Parkinson’s disease diagnosis and progression	Currently available	Spinesin	CSF	Parkinson DiseaseProdromal	Genetic Subjects	Baseline, 6, 12, 24, 36, 48, 60 Months	219
77	Omar Mabrouk, PhD	Biogen	CSF total LRRK2 measurements as a Biomarker in genetic PD	Currently available	LRRK2	CSF	Healthy ControlParkinson DiseaseProdromal	GBA & LRRK2 subjects	Baseline, 24 Months	221
78	Aparna Vasanthakumar, PhD	Abbvie	O-Link in PPMI	Currently available	Targeted proteomics	CSFPlasma		N/A	Baseline, 6, 12, 24, 36, 48, 60 months	222		https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.70183 https://link.springer.com/article/10.1007/s00401-024-02706-0 https://www.nature.com/articles/s41467-023-41122-y https://pubmed.ncbi.nlm.nih.gov/41040736/#:~:text=Methods%3A%20We%20have%20leveraged%20publicly,Explore%20(CSF%20and%20plasma)
79	Anthony Schapira, MD	UCL Medical School	The genome-microbiome axis in the cause of Parkinson disease: Mechanistic insights and therapeutic implications from experimental models and a genetically stratified patient population	Expected Q1 2026	Assessing PD phenotypes in enteric neurons, dopaminergic neurons, astrocytes, microglia	iPSCs	Healthy ControlParkinson Disease	N/A	N/A	223
80	Céline Galvagnion, PhD	University of Copenhagen	Understanding selective neuronal vulnerability in the context of Parkinson's Disease	Expected Q2 2026	Proteomics and lipidomics in dopamine and cortical neurons	iPSCs	Healthy ControlParkinson Disease	LRRK2, iPD	N/A	224
81	Susanna Narkilahti, PhD	University of Tampere	Electrophysiological Phenotype Characterization of iPSC-derived Neuronal Cells with PD-linked LRRK2 Mutations during Network Formation and Alpha-Synuclein Seeded Aggregation	Expected Q1 2026	electrophysiological phenotype	iPSCs	Healthy ControlParkinson DiseaseProdromal	LRRK2 G2019S, LRRK2 R1441G	N/A	227
82	Mark Cookson, PhD	NIH	FOUNDIN[mu]- a microglial resource for PPMI lines	Expected Q2 2026	ATACseq and RNAseq in microglia	iPSCs	Healthy ControlParkinson Disease	N/A	N/A	228		https://doi.org/10.1016/j.xgen.2023.100261 https://doi.org/10.1126/scitranslmed.abp8869
83	Sonia Gandhi, PhD, MD	University College London	Defining mechanisms in neurons and oligodendrocytes that drive progression in Parkinson’s	Expected Q1 2026	High content imaging, transcriptomics in dopamine neurons and oligodendrocytes	iPSCs	Healthy ControlParkinson DiseaseProdromal	iPD, SNCA (A53T), Hyposmic, RBD	N/A	229
84	Rhalena Thomas, PhD	McGill University	A pipeline for massive multiplexing of iPSC-derived dopaminergic neurons and microglia for cohort-scale transcriptomics in PD	Expected Q1 2026	scRNAseq profiling of pooled iPSC dervied neurons and microglia	iPSCs	Healthy ControlParkinson DiseaseProdromal	iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), Hyposmic	N/A	230		https://doi.org/10.1186/s13024-024-00723-x
85	Lezanne Ooi, PhD	University of Wollongong	Metabolic phenotyping in PD dopaminergic neurons and neuronal-glial co-cultures using high-throughput single-cell metabolomics and lipidomics	Expected Q1 2026	Single cell metabolomics and lipidomics in dopamine neurons, Astrocytes, Microglia	iPSCs	Healthy ControlParkinson DiseaseProdromal	iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), Hyposmic	N/A	231
86	Daniel Paull, PhD	Jackson Laboratories	A cohort-wide resource of transcriptomic and morphological phenotypes in defined neural cell types	Expected Q1 2026	RNAseq and cell painting in NGN2 neurons and cortical excitatory neurons	iPSCs	Healthy ControlParkinson DiseaseProdromal	iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), Hyposmic, RBD	N/A	232
87	Laurent Roybon, PhD	Van Andel Research Institute	Uncovering proteomic alterations in Parkinson’s disease using patient-specific iPSC-derived brain cells	Expected Q1 2026	Proteomics in neurons, astrocytes and oligodendrocytes	iPSCs	Healthy ControlParkinson DiseaseProdromal	iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), Hyposmic	N/A	233
88	Laurent Roybon, PhD	Van Andel Research Institute	Biochemical and Omic-based analyses of PD iPSC-derived brain cells	Expected Q1 2026	Multi-omics characterization of diverse cell types (DA neurons & cortical neurons, astrocytes, oligodendrocyte, and microglia)	iPSCs	Healthy ControlParkinson DiseaseProdromal	iPD, GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T), Hyposmic	N/A	234, 266
89	Lalitha Madhavan, PhD, MD	University of Arizona	Deep phenotyping of PD relevant mitochondrial and autophagic mechanisms in human iPSC-derived neural cells	Currently available	Mitochondrial and autophagic phenotypes/alpha-synuclein	iPSCs	Healthy ControlParkinson Disease	N/A	N/A	235		https://doi.org/10.1016/j.pneurobio.2023.102501 https://doi.org/10.1016/j.pneurobio.2023.102501 https://doi.org/10.1016/j.nbd.2025.107222
90	Souvik Modi, PhD	ESYA Labs	ESYA PD360: A multi-parametric platform for establishing a novel lysosome-based biomarker and identifying therapeutic interventions for Parkinson’s Disease	Currently available	RNAseq, pH, calcium and autophagy analyses in fibroblasts	Fibroblasts	Healthy ControlParkinson Disease	N/A	N/A	236		https://doi.org/10.1002/alz.080277
91	Luis Concha, PhD	Amprion	Analysis of CSF samples	Ongoing availability	Alpha-Synuclein Seeds	CSF	Healthy ControlParkinson DiseaseProdromal	N/A	Baseline, 6, 12 Months	237		https://doi.org/10.1016/S1474-4422(23)00109-6 https://doi.org/10.1016/s1474-4422(25)00157-7
92	Daniel Ysselstein, PhD	Vanqua Bio	Glucocerebrosidase Activation as a Therapeutic Strategy for Parkinson’s Disease	Currently available	Longitudinal assessment of GCase activity, insoluble aSyn, sphingolipids, and lysosomal dysfunction in DA neurons	iPSCs	Healthy ControlParkinson Disease	GBA	N/A	239
93	Nick Hertz, PhD	Mitokinin	Assessing pS65 Ubiquitin levels in biofluids as a biomarker for Parkinson's Disease	Currently available	pS65Ub	CSFPlasma	Healthy ControlParkinson DiseaseProdromal	N/A	Baseline, 6, 12, 24, 36, 48, 60 months	240
94	Hilde Nilsen, PhD	Oslo University Hospital	Mitochondrial Transcription regulation via Base Excision Repair	Expected Q1 2026	NTHL1	iPSCs	Healthy ControlParkinson DiseaseProdromal	SNCA	N/A	241
95	Luis Concha, PhD	Amprion	Evaluation of αSyn seed levels in prodromal cases by means of a semi-quantitative seed amplification assay & Validation of Clinical Accuracy of the Rapid Qualitative αSynuclein Seed Amplification Assay in the Amprion Clinical Laboratory	Partially available	Alpha-Synuclein Seeds	CSF	Healthy ControlParkinson DiseaseSWEDD (legacy)	N/A	24-hour samples	242		https://doi.org/10.1212/WNL.0000000000210279 https://doi.org/10.1016/s1474-4422(25)00157-7
96	David Sulzer, PhD	Research Foundation for Mental Hygiene, Inc.	Adaptive immunity in the etiology and progression of Parkinson’s disease	Currently available	aSyn-reactive T cells	PBMCs	Healthy ControlParkinson DiseaseProdromal	N/A	N/A	245		https://doi.org/10.1172/JCI180478 https://doi.org/10.1038/s41531-025-01001-3
97	Saranna Fanning, PhD	Brigham & Women's Hospital, Inc.	Advancing Clinical Relevance of a Lipase as a Therapeutic Target for Parkinson’s Disease in PPMI Subject Derived iPSCs	Expected Q1 2026	Monoacylglycerol lipase (MGL)	FibroblastsiPSCs	Healthy ControlParkinson Disease	SNCA,GBA	N/A	247
98	Ivan Martinez-Valbuena, PhD	University of Toronto	Developing a standardized skin-based alpha-synuclein seeding amplification assay for the diagnosis of Parkinson’s disease	Currently available	SAA	Skin	Healthy ControlParkinson Disease	N/A	BL, 6, 48,	248
99	Nobutaka Hattori, MD, PhD	Juntendo	Validation of a Serum Synuclein Seed Amplification Assay IP/SAA in PPMI	Expected Q1 2026	SAA	Serum	Parkinson Disease	N/A	Baseline, 6, 12 Months	249
100	Joanne Trinh, PhD	Institute of Neurogenetics, Luebeck	Interaction of the environment and somatic modifiers in mitochondrial genes on disease penetrance	Expected Q3 2027	Mitochondrial DNA variations	DNA from whole blood	Healthy ControlParkinson DiseaseProdromalSWEDD (legacy)	N/A	SC and Baseline	250
101	Bastian Zinnhardt, PhD	Roche	Linking inflammasome activation biomarkers with general inflammation and neurodegeneration markers	Expected Q1 2026	ASC, HMGB1	CSF	Healthy ControlParkinson Disease	N/A	Baseline, 12, 24, 48 months	253
102	Maximilliano Gutierrez, PhD	The Francis Crick Institute	The impact of the LRRK2 G2019S mutation on lysosomal function in macrophages	Expected Q1 2026	LRRK2 kinase activity	iPSCs	Parkinson Disease	N/A	N/A	254
103	Sri Ramulu, Pullagura, PhD	FNIH	Identification of disease progression-predictive autoantibody biomarker signatures in the plasma of PD patients	Currently available	Targeted autoantibodies (Sengenics i-Ome Discovery IgG/IgM, AMP PD)	Plasma	Healthy ControlParkinson Disease	N/A	Healthy Control: Baseline and 48 months; PD: 3 visits Baseline to 48 months	256
104	Luis Concha, PhD	Amprion	Evaluation of skin as a matrix for the detection and potential quantification of α- synuclein seeds in subjects with Parkinson’s disease	Currently available	aSyn SAA	Skin	Healthy ControlParkinson DiseaseProdromal	N/A	N/A	259
105	Roland Heym, PhD	AbbVie	Evaluation of pathological alpha-synuclein in skin biopsies as potential biomarker for Parkinson’s disease	Partially available	aSyn SAA	Skin	Healthy ControlParkinson DiseaseProdromal	N/A	Baseline, 36 months, 72 months, >72 months	262
106	Roland Heym, PhD	AbbVie	Evaluation of pathological alpha-synuclein in skin biopsies as potential biomarker for Parkinson’s disease	Currently available	pS129-aSyn	Skin	Healthy ControlParkinson DiseaseProdromal	N/A	Baseline, 36 months, 72 months, >72 months	301
107	Roland Heym, PhD	AbbVie	Evaluation of pathological alpha-synuclein in skin biopsies as potential biomarker for Parkinson’s disease	Partially available	aSyn SAA	Skin	Healthy ControlParkinson Disease	N/A	N/A	302
108	Omar Mabrouk, PhD	Biogen	Surveying endo-lysosomal function in PD subtypes using an LC-MS-based 12-plex in CSF	Currently available	LAMP1, LAMP2, Cathepsins B, D, F, L, S GM2A, GBA, GPNMB, Ubiquitin, LC3	CSF	Healthy ControlParkinson Disease	GBA & LRRK2 subjects	Baseline, 12, and 24 months	264
109	Pier Giorgio Mastroberardino, PhD	University of L'Aquila	Alterations in DNA repair mechanisms in PD nervous system cells and their correlation with clinical variables	Expected Q1 2027	DNA damage markers	iPSCs	Healthy ControlParkinson Disease	N/A	N/A	267
110	David Vocadlo, PhD	Simon Fraser University	Generation of isogenic control lines for the iPSCs derived from Parkinson’s Disease patients carrying GBA or LRRK2 mutations and assessment of GCase activity	Expected Q4 2026	GCase activity	iPSCs	Parkinson Disease	LRRK2, GBA, GBA non-manifesting carriers	N/A	268
111	Philip Milliken, PhD	Galvani Bioelectronics	Splenic nerve stimulation to reduce inflammation driven Parkinson’s progression and LRRK2 mutation-driven Parkinson’s risk	Expected Q2 2026	Cytokines, including TNFalpha	iPSCs	Healthy ControlParkinson Disease	LRRK2	N/A	269
112	Nic Dzamko, PhD	University of Sydney​	Strainotyping Synuclein Aggregates in Disease	Expected Q3 2026	Synuclein strain aggregation	iPSCs	Healthy ControlParkinson DiseaseProdromal	GBA & LRRK2 subjects	N/A	270
113	Julian Sefrin, PhD	AbbVie	Evaluation of polyamines as disease and progression biomarkers in the CSF of Parkinson´s disease patients	Expected Q2 2026	Polyamines	CSF	Healthy ControlParkinson DiseaseProdromal	N/A	Baseline, 6, 12, 24, 36, 48, 60 months	273
114	Roland Heym, PhD	AbbVie	Validation of monoclonal antibody-based ligand binding assay for DDC as potential diagnostic biomarker for Parkinson’s disease	Currently available	DOPA decarboxylase (DDC)	CSF	Healthy ControlParkinson DiseaseSWEDD (legacy)	N/A	Healthy Control and PD: Baseline and 36 months; SWEDD: Baseline	274
115	Sonia Gandhi, PhD, MD	University College London	Delineating neuronal and glial mechanisms of insulin resistance in iPSC models of Parkinson's	Expected Q2 2027	Phosphorylated akt, targeted protein/peptide levels focused on kinases. Transcriptomic (RNA) data, cell viability.	iPSCs	Healthy ControlParkinson DiseaseProdromal	SNCA (A53T)	N/A	275
116	Mark Mintun, PhD	Eli Lilly & Co.	Assessment of plasma ptau217 in deeply biologically and phenotypically characterized neuronal a-synuclein disease (NSD) and related disorders in PPMI cohorts	Currently available	Tau	Plasma	Healthy ControlParkinson Disease	N/A	Baseline, 24, 36, 60 months	276
117	Brit Mollenhauer, MD	University of Goettingen	Multiplex proteome analysis for NSD in PPMI to identify progression biomarkers for early disease therapeutic trials	Currently available	Targeted Proteomics (O-link)	CSF	Healthy ControlParkinson DiseaseProdromal	N/A	Baseline, Visit 08	277
118	Benoit Lehallier, PhD	Alkahest	CHRONOS-PD: the longitudinal molecular time machine of Parkinson’s Disease	Expected Q2 2026	Unbiased proteomics (Somalogics, O-link, MS and NULISA)	Plasma	Healthy ControlParkinson Disease	N/A	N/A	280
119	Brit Mollenhauer, MD	University of Goettingen	Quantification of previously identified Dopa Decarboxylase, Midkine and Neurofilament light Chain as progression biomarker in stage 2/3 Parkinson’s disease to support prevention trials	Expected Q4 2026	DDC	CSFPlasma	Healthy ControlParkinson DiseaseProdromal	N/A	Baseline, Visits 04 and 08	281
120	Nicholas Ashton, PhD	Banner Health	NuLISAseq proteomics investigation (Inflammation & CSF panels) of PPMI CSF samples (NSD & non-NSD)	Currently available	NuLISA CNS & Inflammation panels	CSF	Healthy ControlParkinson DiseaseProdromal	N/A	BL or V02, V8-V12, HC	282
121	Tatiana Foroud, PhD	Indiana University	Assessment of CSF and plasma biomarkers of dementia and neurodegeneration in deeply biologically and phenotypically characterized neuronal a-synuclein disease (NSD) and related disorders PPMI cohorts	Currently available	NFL and GFAP (plasma); AB40/42 and p-tau 181 in CSF	CSFPlasma	Healthy ControlParkinson DiseaseProdromal	N/A	CSF: BL or V02, V8-V12, HC; Plasma: BL or V02, V8-12, V14-V18	283
122	David Walt, PhD	Harvard University	Measurement of alpha-synuclein in plasma EVs after automated SEC isolation	Expected Q3 2026	aSyn SAA in EV	Plasma	Healthy ControlParkinson Disease	N/A	N/A	284
123	George Tofaris, PhD, MD	University of Oxford	Development of an alpha-synuclein blood biomarker for clinical readiness	Expected Q3 2026	Total aSyn in serum L1CAM-EVs	Serum	Healthy ControlParkinson Disease	LRRK2, GBA, GBA non-manifesting carriers	Baseline	285
124	Erez Eitan, PhD	Neurodex Inc	α-Synuclein in Neuron-Derived Blood Extracellular Vesicles: A Biomarker for the Diagnosis and Staging of Neuronal α-Synuclein Diseases	Expected Q2 2026	aSyn SAA in EVs	Plasma	Healthy ControlParkinson Disease	N/A	N/A	286
125	Tuomas Knowles, PhD	University of Cambridge	Parallelized digital seed amplification assay for PD biomarker development	Expected Q3 2026	Quantitative SAA	CSF	Healthy ControlParkinson DiseaseProdromal	N/A	Various	287
126	Jim Eubanks, PhD	Octave Bioscience	Development of a protein biomarker panel to measure Parkinson’s disease activity and progression	Currently available	NuLISA CNS & Inflammation panels	Plasma	Healthy ControlParkinson DiseaseProdromal	N/A	BL or V02, V8-12, V14-V18	288
127	Philip Verghese, PhD	C2N Diagnostics	MTBR tau 243 and PrecivityAD2 assays in PPMI Biosamples	Currently available	PrecivityAD2	Plasma	Healthy ControlParkinson DiseaseProdromal	N/A	BL or V02, V8-V12, HC	292
128	Philip Verghese, PhD	C2N Diagnostics	MTBR tau 243 and PrecivityAD2 assays in PPMI Biosamples	Currently available	MTBR tau 243	CSF	Healthy ControlParkinson DiseaseProdromal	N/A	BL or V02, V8-12, V14-V19	307
129	Jim Eubanks, PhD	Octave Bioscience	Development of a protein biomarker panel to measure Parkinson’s disease activity and progression	Currently available	Targeted proteomics (O-link)	Plasma	Healthy ControlParkinson DiseaseProdromal	N/A	BL or V02, V8-12, V14-V18	293
130	Mark Cookson, PhD	NIH	Assessing PD-relevant toxicants on neurons and microglia and their crosstalk	Expected Q1 2027	ATAC and RNA-seq data from iPSC lines in response to environmental exposures. Cell imaging and viability data will also be generated.	iPSCs	Healthy ControlParkinson Disease	N/A	N/A	294, 324
131	Sonia Gandhi, PhD, MD	University College London	Dissecting the interaction between air pollution and Parkinson's disease	Expected Q1 2027	Transcriptomic data, inflammatory markers DA Neurons, microglia for multiple exposure conditions.	iPSCs	Healthy ControlParkinson DiseaseProdromal	SNCA (A53T)	N/A	295
132	Lezanne Ooi, PhD	University of Wollongong	Phenotyping environmental exposure to long-lasting chemicals, nanoplastics and pesticides in iPSC dopaminergic neurons and glia	Expected Q3 2026	Targeted metabolomics data; tabular data	iPSCs	Healthy ControlParkinson DiseaseProdromal	GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T),	N/A	296
133	Dan Paull, PhD	The Jackson Laboratory	Establishing a proof-of-concept automated platform for the study of gene x environment-based toxicity in human cellular models of Parkinson’s disease	Expected Q3 2026	Cellular imaging and profiling data (comparing environmental exposure and control samples)	iPSCs	Healthy ControlParkinson DiseaseProdromal	GBA N370S, LRRK2 G2019S, LRRK2 R1441G, SNCA (A53T),	N/A	297
134	Silvia Bolognin, PhD	Maastrict University	NR2F1 role in PD	Expected Q1 2027	NR2F1	iPSCs	Healthy ControlParkinson Disease	LRRK2-G2019S	N/A	298
135	Jennifer Lamoureux, PhD	Amprion	PPMI aSyn SAA Analysis	Ongoing availability	Alpha-Synuclein Seeds	CSF	Healthy ControlParkinson DiseaseProdromal	N/A	Screening	299
136	Kim Henriksen, PhD	Nordic Bioscience	alpha-synuclein fragments in serum predict disease progression in Parkinson's Disease	Currently available	Calpain-1 generated aSyn fragments (α-syn-C)	Serum	Healthy ControlParkinson Disease	N/A	BL, V01, V02, V04	300
137	Uri Ashery, PhD	Tel Aviv University	Developing a novel platform for patient selection and disease tracking using super-resolution microscopy and AI	Expected Q3 2026	Synuclein Aggregates	Skin	Healthy ControlParkinson Disease	N/A	N/A	308
138	Indranath Ghosh, PhD	Congruence Therapeutics Inc	Allosteric Small Molecule Therapies for Treating GBA1-PD	Expected Q3 2026	VDAC1 oligomerization	iPSCs	Healthy ControlParkinson Disease	GBA1 N409S	N/A	310
139	Joseph Powell, PhD	Garvan Institute fo Medical Research	Defining the role of genetics on the cellular and molecular determinants of variable penetrance in Parkinson’s disease	Expected Q1 2031	Multi-omic and imaging characterization of differentiated cell types derived from iPSCs.	iPSCs	Healthy ControlParkinson DiseaseProdromalSWEDD (legacy)	GBA, LRRK2, SNCA,	N/A	311
140	Christopher Bunker, PhD	Alamar BioSciences	PPMI LITE 2025-2026 Alamar Proteomics	Expected Q3 2026	NuLISA CNS & Inflammation panels	CSFPlasma	Healthy ControlParkinson DiseaseProdromal	Genetic PD and non-manifesting carriers	BL or V02, V8-12, V14-V18	312
141	Scott Hutton, PhD	Metabolon, Inc.	Longitudinal Lipidomic and Metabolomic Profiling of CSF, Plasma, and Urine from PPMI Participants	Expected Q3 2026	Metabolomics	CSFPlasma	Healthy ControlParkinson DiseaseProdromal	Genetic PD and non-manifesting carriers	BL or V02, V8-12, V14-V18	313
142	Josh Porter	Olink Proteomics Inc	PPMI LITE 2025-2026 O-link Proteomics	Expected Q3 2026	Targeted proteomics (O-link)	CSFPlasma	Healthy ControlParkinson DiseaseProdromal	Genetic PD and non-manifesting carriers	BL or V02, V8-12, V14-V18	314
143	Oliver Uecke, PhD	Lipotype Inc	Lipid Analysis of Plasma and Urine Samples	Expected Q2 2027	Lipidomics	PlasmaUrine	Healthy ControlParkinson DiseaseProdromal	Genetic PD and non-manifesting carriers	BL or V02, V8-12, V14-V18	315
144	Bill Piu Chan, MD, PhD	Xuanwu Hospital, Capital Medical University	A Pilot Study to Assess Diagnostic Sensitivity and Specificity for PD using Blood a-synuclein Seed Amplification Assay Developed at Xuanwu Hospital of Capital Medical University	Expected Q3 2026	Synuclein Seeds	Plasma	Healthy ControlParkinson Disease	N/A	V01	316
145	Roland Heym, PhD	Abbvie	Accelerating Medicines Partnership in Parkinson’s Disease and Related Disorders (AMP PDRD): DDC Biomarker Study	Expected Q3 2026	DDC	CSFPlasma	Healthy ControlParkinson Disease	N/A	BL, V04, V08	317
146	Joshua Shulman, PhD, MD	Baylor College of Medicine	Investigating sphingolipid perturbations caused by SPTSSB Parkinson's disease risk variant	Expected Q1 2028	Shpingolipids	iPSCs	Healthy ControlProdromal	heterozygous, homozygous, or non-carriers for SPTSSB variants	N/A	319
147	Lalitha Madhavan, PhD, MD	University of Arizona	Studying mechanisms of sporadic PD using iPSC-derived cells	Expected Q1 2027		iPSCs	Healthy ControlParkinson Disease	N/A	N/A	320
148	Tyler Hulett, PhD	CDI Laboratories Inc	Investigation of antibody repertoires associated with Parkinson’s disease	Expected Q1 2027	Autoantibodies	Serum	Healthy ControlParkinson Disease	LRRK2 PD and NMC, GBA PD	BL or SC	323